Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Proofpoint Stock Rose 40% in the Last Month

By Chris Lau, InvestorPlace Contributor

Proofpoint stock rose sharply ahead of and after its Q4 earnings report. Why is this software security stock up?

3 Biotech Stocks That Pay Solid Dividends

By Chris Lau, InvestorPlace Contributor

Biotech stocks offer more than just capital gains; some of them pay dividends. Here are three dividend-paying biotechs to consider.

What to Do After Pyxus International Stock Rallied by Over 25%

By Chris Lau, InvestorPlace Contributor

Pyxus stock rallied by over 25% on no news. Are speculators betting on a strong upcoming earnings report from PYX?

QCOM’s Future Will Not Be Revealed With Tomorrow’s Earnings

By Chris Lau, InvestorPlace Contributor

QCOM reports quarterly earnings Wednesday after the close, but the FTC case against Qualcomm will be what dictates the stock's next move.

7 Semiconductor Stocks to Buy Now 

By Chris Lau, InvestorPlace Contributor

Thanks to strong earnings reports, semiconductor stocks are already rallying, after weeks of underperformance and fear. What do you buy now?

Load More